Kangfang Biotech (9,926), which plunged nearly 45% in the morningcryptogamingmobile.HK) Pull up in the afternooncryptogamingmobile, the current decline has narrowed to 13%. Kangfang Biotech responded to a sharp dropcryptogamingmobile, ASCO disclosed that the HR corresponding to AK112 progression-free survival reached 0cryptogamingmobile.46, which is the core data for evaluating clinical study results. The data results are excellent and there is no saying that they are lower than expected. Currently, the data of AK112 -301 has been accepted as an oral report by the 2024 ASCO Conference due to its excellent results. According to the organizer's plan, it will be published globally on June 1.

In addition, Kangfang Biotech announced that the National Food and Drug Administration (NMPA) has approved the new drug marketing application of the world's first new bispecific antibody drug, Idafone (Evosi injection, PD-1/VEGF) independently developed by the company. The indication is combination chemotherapy for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC) with EGFR mutations that have progressed after treatment with epidermal growth factor receptor (EGFR) tyrosine stimulation inhibitors (TKI).